Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Navinci logo — Illuminating function is spatial proteomics

Navinci

Illuminating function is spatial proteomics

Founded 2004 Sweden Sweden 31 employees Series A Total: $90.00M Biotechnology, Health Care

General Information

Company Name Navinci
Founded Year 2004
Location Sweden Sweden +1
Employees 31
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when Navinci moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Navinci

Navinci is a Swedish biotech company founded in 2004, which specializes in developing innovative solutions for the study of protein interactions. The company's flagship product, Naveni Proximity Ligation Technology, is at the forefront of innovation in spatial proteomics, enabling sensitive and specific detection and quantification of protein interactions and post-translational modifications. With a strong legacy in in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in this field. The company's latest focus is on target-specific kits within immuno-oncology, designed to help researchers visualize interactions such as PD1/PD-L1 and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. In July 2022, Navinci secured a kr90.00M Series A investment from notable investors including Segulah Medical Acceleration, Beijer Ventures, Nxt2b, and Landegren Gene Technology. This investment signifies confidence in Navinci's potential to provide reliable and innovative tools for visualizing and interpreting protein interplay, thus pushing forward the understanding of cell biology and bringing precision to spatial proteomics in the fields of biotechnology and health care.

Taxonomy: Spatial Proteomics, Proximity Ligation, In Situ Assays, Protein Interactions, Post-Translational Modifications, Immuno-Oncology, Biomarker Detection, Cancer Research, Cell Biology, Protein Quantification, Diagnostic Technology, Biotech Innovation, Protein Visualization, Biological Interactions, Precision Medicine

Services & Products

In situ proximity ligation assay-based solutions for protein interaction and modification analysis

Target Customers

Biomedical researchers pharmaceutical companies academic institutions CROs

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 4
Investor Investor
•••• •••• 		12 Jul 2022

FAQ About Navinci

Illuminating function is spatial proteomics
Navinci was founded in 2004.
Navinci is headquartered in Sweden.
Navinci operates in the following industries: Biotechnology, Health Care.
Navinci has approximately 31 employees.
Navinci has completed 1 funding round, raising a total of $90.00M. The latest funding stage is Series A.
Navinci offers: In situ proximity ligation assay-based solutions for protein interaction and modification analysis.

We're actively collecting intelligence on Navinci.

Track Navinci to get notified

Don't just browse. Track.

Signal Tracker monitors Navinci and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy